NCT00152893

To Determine if Chromium Nicotinate Supplementation Will Improve Insulin Resistance in HIV Patients With Metabolic Abnormalities

The Effects of Chromium Supplementation on Glucose and Lipid Metabolism in Patients With HIV Infection

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 52 (actual)
• Sponsor: Johane Allard · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

In HIV patients, fasting insulin levels decrease with chromium supplementation. This study is to determine if chromium nicotinate supplementation at 400ug/day for 16 weeks will improve insulin resistance in HIV patients with metabolic abnormalities.

Detailed description

This study is a randomized, double-blind, placebo-controlled, crossover study where patients will be supplemented for 16 weeks with either chromium nicotinate 400 ug/day or placebo and then crossover to the opposite treatment for another 16 weeks. Each soft gel capsule of chromium contains 200ug of chromium and patients will take 1 capsule twice a day or its placebo. Placebo contains di-calcium phosphate in a soft gel capsule and its appearance is similar to the chromium capsules.

Conditions

• HIV Infections

Interventions

Type	Name	Description
DRUG	chromium nicotinate
DRUG	Placebo

Timeline

• Start date: 2002-08-01
• Primary completion: 2008-02-01
• Completion: 2008-02-01
• First posted: 2005-09-09
• Last updated: 2013-07-19

Locations

1 site across 1 country: Canada